Dr. Yi-Bin Chen, MD
Claim this profileMassachusetts General Hospital
Studies Acute Myeloid Leukemia
Studies T-Lymphoblastic Leukemia/Lymphoma
11 reported clinical trials
19 drugs studied
Area of expertise
1Acute Myeloid Leukemia
HLA-A positive
HLA-A negative
HLA positive
2T-Lymphoblastic Leukemia/Lymphoma
HLA-A positive
HLA-A negative
HLA positive
Affiliated Hospitals
Clinical Trials Yi-Bin Chen, MD is currently running
Bone Marrow/Kidney Transplant
for Blood Disorders & Chronic Kidney Disease
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney rejection and less need for long-term use of anti-rejection drugs. Traditionally, very strong cancer treatment drugs (chemotherapy) and radiation are used to prepare a subject's body for bone marrow transplant. This is associated with a high risk for serious complications, even in subjects without kidney disease. This therapy can be toxic to the liver, lungs, mucous membranes, and intestines. Additionally, it is believed that standard therapy may be associated with a higher risk of a complication called graft versus host disease (GVHD) where the new donor cells attack the recipient's normal body. Recently, less intense chemotherapy and radiation regimens have been employed (these are called reduced intensity regimens) which cause less injury and GVHD to patients, and thus, have allowed older and less healthy patients to undergo bone marrow transplant. In this study, a reduced intensity regimen of chemotherapy and radiation will be used with the intent of producing fewer toxicities than standard therapy. Typical therapy following a standard kidney transplant includes multiple lifelong medications that aim to prevent the recipient's body from attacking or rejecting the donated kidney. These are called immunosuppressant drugs and they work by "quieting" the recipient's immune system to allow the donated kidney to function properly. One goal in our study is to decrease the duration you will need to be on immunosuppressant drugs following your kidney transplant as the bone marrow transplant will provide you with the donor's immune system which should not attack the donor kidney.
Recruiting1 award N/A11 criteria
Experimental Drug
for Leukemia Post-Stem Cell Transplant
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Recruiting1 award Phase 1
More about Yi-Bin Chen, MD
Clinical Trial Related8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Yi-Bin Chen, MD has experience with
- Orca-T
- Fludarabine
- Cyclosporins
- Tacrolimus
- Alemtuzumab
- Mycophenolate Mofetil
Breakdown of trials Yi-Bin Chen, MD has run
Acute Myeloid Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yi-Bin Chen, MD specialize in?
Yi-Bin Chen, MD focuses on Acute Myeloid Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved HLA-A positive patients, or patients who are HLA-A negative.
Is Yi-Bin Chen, MD currently recruiting for clinical trials?
Yes, Yi-Bin Chen, MD is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Yi-Bin Chen, MD has studied deeply?
Yes, Yi-Bin Chen, MD has studied treatments such as Orca-T, Fludarabine, Cyclosporins.
What is the best way to schedule an appointment with Yi-Bin Chen, MD?
Apply for one of the trials that Yi-Bin Chen, MD is conducting.
What is the office address of Yi-Bin Chen, MD?
The office of Yi-Bin Chen, MD is located at: Massachusetts General Hospital, Boston, Massachusetts 02114 United States. This is the address for their practice at the Massachusetts General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.